RxDoctor Payments Data

Dean Bailey, MD

Family Medicine · van Wert, OHNPI 1780704445

Payments from drug & device makers

$715in general payments, 2019–2025

Across 10 payments — averaging $71.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$143
  • Novo Nordisk$135
  • Urovant Sciences Inc$125
  • Amgen$121
  • Mylan Specialty L.p.$111
  • AstraZeneca$61
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$143
Novo Nordisk2$135
Urovant Sciences Inc1$125
Amgen1$121
Mylan Specialty L.p.1$111
AstraZeneca1$61
Abbott1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$715 in reported general payments places this provider in the 55th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$171,601
Medicare patients
344
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$105,052
EliquisApixaban88$66,788
FarxigaDapagliflozin Propanediol51$45,796
JanuviaSitagliptin Phosphate29$32,745
TrulicityDulaglutide21$22,136
XareltoRivaroxaban14$20,854
JardianceEmpagliflozin11$19,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,680
Repatha SyringeEvolocumab15$13,700
Breo ElliptaFluticasone/Vilanterol16$8,849
TradjentaLinagliptin11$6,680
Tresiba Flextouch U-100Insulin Degludec14$6,591
MyrbetriqMirabegron14$5,904
Advair HfaFluticasone Propion/Salmeterol17$5,694
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$5,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$105,05287 claims
AstraZenecaFarxiga, Symbicort$61$48,85065 claims
GSKTrelegy Ellipta, Breo Ellipta$143$23,52937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in van Wert

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →